(2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol | 704902-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
• 英文别名: (3S,4S,5R)-2-Aminomethyl-5-hydroxymethyl-pyrrolidine-3,4-diol
• CAS: 704902-18-1
• 化学式: C₆H₁₄N₂O₃
• 分子量: 162.189
• InChiKey: NJOZFAFEQVQFJI-KAZBKCHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  98.7
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯甲酰)丙酸 、 (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成 4-(4-Chlorophenyl)-N-[[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]methyl]-4-oxobutanamide
  参考文献：
  名称：

  从天然产物启发的吡咯烷支架到新型人类高尔基体α-甘露糖苷酶II抑制剂的开发

  摘要：

  一点启发：本文描述了系统地制备16种以自然产物为灵感的多氢基吡咯烷基异构支架的方法。每个支架都具有四个立体定位中心和一个外氨基氨基甲基部分，可实现快速的取代基多样性。为了举例说明生物学应用，这些新的特权支架被用于发现新的人类高尔基α-甘露糖苷酶II抑制剂。最有效的抑制剂表现出竞争行为，K i值为24 nM。

  DOI：

  10.1002/asia.201300680
• 作为产物：
  描述：

  C₅H₉NO₄ 在 氢气 、 palladium(II) hydroxide 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 50.0 ℃ 、101.33 kPa 条件下， 反应 22.17h， 生成 (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
  参考文献：
  名称：

  从天然产物启发的吡咯烷支架到新型人类高尔基体α-甘露糖苷酶II抑制剂的开发

  摘要：

  一点启发：本文描述了系统地制备16种以自然产物为灵感的多氢基吡咯烷基异构支架的方法。每个支架都具有四个立体定位中心和一个外氨基氨基甲基部分，可实现快速的取代基多样性。为了举例说明生物学应用，这些新的特权支架被用于发现新的人类高尔基α-甘露糖苷酶II抑制剂。最有效的抑制剂表现出竞争行为，K i值为24 nM。

  DOI：

  10.1002/asia.201300680

文献信息

• [EN] TREATMENT OF FABRY DISEASE<br/>[FR] TRAITEMENT DE LA MALADIE DE FABRY
  申请人：ACADEMIA SINICA

  公开号：WO2017222881A1

  公开（公告）日：2017-12-28

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with -COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文揭示了聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗患有或疑似患有FD的受试者的方法。该方法包括步骤，向受试者施用化合物I式，其盐、酯或溶剂化物的治疗有效量，其中：R1是H，或C1-3胺，可选地取代为-COR2；R2是烷基或烯烃，可选地取代为环烷基或苯基，其至少有一个取代基选自卤素，烷基，卤代烷基和烷氧基的群体；以缓解、减轻和/或预防与FD相关的症状。根据本公开的优选实施例，化合物I式是人类溶酶体α-半乳糖苷酶A（α-Gal A）的突变体的伴侣蛋白。
• Syntheses and Glycosidase Inhibitory Activities of 2-(Aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Derivatives
  作者：Florence Popowycz、Sandrine Gerber-Lemaire、Catherine Schütz、Pierre Vogel

  DOI：10.1002/hlca.200490078

  日期：2004.4

  New 2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol derivatives were synthesized from (5S)-5-[(trityloxy)methyl]pyrrolidin-2-one (6) (Schemes 1 and 2) and their inhibitory activities toward 25 glycosidases assayed (Table). The influence of the configuration of the pyrrolidine ring on glycosidase inhibition was evaluated. (2R,3R,4S,5R)-2-[(benzylamino)methyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol

  由（5 S）-5-[[三苯氧基）甲基]吡咯烷丁-2-酮（6）合成新的2-（氨基甲基）-5-（羟甲基）吡咯烷-3,4-二醇衍生物（方案1和2）测定了它们对25种糖苷酶的抑制活性（表）。评估了吡咯烷环的构型对糖苷酶抑制的影响。发现（2 R，3 R，4 S，5 R）-2-[（（苄氨基）甲基] -5-（羟甲基）吡咯烷-3,4-二醇（（+）- 21）是一种很好的选择性化合物杰克豆（K i = 1.2μM）和杏仁（α-甘露糖苷酶）的α-甘露糖苷酶抑制剂K i = 1.0μM）。非苄基化衍生物（2 R，3 R，4 S，5 R）-2-（氨基甲基）-5-（羟甲基）吡咯烷-3,4-二醇（（+）- 22）的选择性丧失α-半乳糖苷酶，β-半乳糖苷酶，β-葡萄糖苷酶和α - N-乙酰半乳糖苷酶。
• Treatment of Fabry disease
  申请人：Academia Sinica

  公开号：US10995067B2

  公开（公告）日：2021-05-04

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文公开了一种聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗法布里病或疑似法布里病受试者的方法。该方法包括以下步骤：向受试者施用治疗有效量的式(I)化合物、其盐、酯或溶液，其中：R1是H，或任选被-COR2取代的C1-3胺；R2是烷基或烯基，任选被环烷基或苯基取代，环烷基或苯基具有至少一个选自由卤代、烷基、卤代烷基和烷氧基组成的组的取代基；从而改善、减轻和/或预防与FD相关的症状。根据本公开的优选实施方案，式（I）化合物是突变的人溶酶体 α-半乳糖苷酶 A（α-Gal A）的合子。
• Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease
  作者：Wei-Chieh Cheng、Jen-Hon Wang、Wen-Yi Yun、Huang-Yi Li、Jia-Ming Hu

  DOI：10.1016/j.ejmech.2016.10.004

  日期：2017.1

  The rapid discovery of a pharmacological chaperone toward human alpha-Gal A for the treatment of Fabry disease is described. Two polyhydroxylated pyrrolidines with the (3R,4S,5R) configuration pattern underwent rapid substituent diversity by conjugating the primary aminomethyl moiety of each with a variety of carboxylic acids to generate two libraries (2 x 60 members). Our bioevaluation results showed one member with the (2R,3R,4S,5R) configuration pattern and bearing a 5-cyclohexylpentanoyl group as a substituent moiety possessed sufficient chaperoning capability to rescue alpha-Gal A activity in the lymphocyte of the N215S Fabry patient-derived cell line and other alpha-Gal A mutants in COS7 cells. (C) 2016 Elsevier Masson SAS. All rights reserved.
• A convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP
  作者：En-Lun Tsou、Yao-Ting Yeh、Pi-Hui Liang、Wei-Chieh Cheng

  DOI：10.1016/j.tet.2008.10.096

  日期：2009.1

  A practical method for the synthesis of five-membered iminocyclitols, pyrrolidine alkaloids bearing multiple hydroxyl substituents, has been developed. All of the eight key intermediates, enantiopure tri-O-benzyl cyclic nitrones, are prepared from four cheap, readily available D-aldopentoses. The nucleophilic addition of cyclic nitrones with vinyl magnesium chloride and TMSCN shows high 2,3-trans stereoselectivity. To construct the 2,3-cis configurations, inversion of the C-2 nitrile group is achieved via an elimination-reduction sequence. Using this approach, five isomers of DMDP and six isomers of ADMDP are prepared efficiently. In the biological evaluation, iminocyclitol 27 is a new and potent inhibitor against beta-hexosaminidase with an IC50 value of 0.2 mu M. (C) 2008 Elsevier Ltd. All rights reserved.